AhlulBayt News Agency: An Iranian knowledge-based company has made a new generation of targeted medicines which increase the life of cancerous patients.
Ali Aqajani, director of business development of a knowledge-based company, said, "This year we have gained access to a very new generation of antibody medicines which were exclusively in the hand of a British company."
According to Pars Today, this company has attained the generation of anti-cancer medicines with the technology of Antibody- ADCs).
This technology takes medicine to the cancerous tissue via targeted therapy and gives the physician a compound of immunotherapy and chemotherapy in the form of a medicine.
Aqajani added, "This medicine is named Tederox and used to treat breast cancer and some digestive cancers. It can increase the life of cancerous patients manifold and, due to targeted therapy, less dose is injected to the body so that we won't have the common effects of cancer medicines like hair loss or weight loss; and finally, we will witness higher effectiveness."
Pointing to the new medicine's notable prevention of cancer recurrence, he said, "Presently, we are in the phase of mass production of this medicine and the price is less than %10 of the foreign brand. The foreign sample of the medicine is $3000 and we supply it at $200."
/129
Ali Aqajani, director of business development of a knowledge-based company, said, "This year we have gained access to a very new generation of antibody medicines which were exclusively in the hand of a British company."
According to Pars Today, this company has attained the generation of anti-cancer medicines with the technology of Antibody- ADCs).
This technology takes medicine to the cancerous tissue via targeted therapy and gives the physician a compound of immunotherapy and chemotherapy in the form of a medicine.
Aqajani added, "This medicine is named Tederox and used to treat breast cancer and some digestive cancers. It can increase the life of cancerous patients manifold and, due to targeted therapy, less dose is injected to the body so that we won't have the common effects of cancer medicines like hair loss or weight loss; and finally, we will witness higher effectiveness."
Pointing to the new medicine's notable prevention of cancer recurrence, he said, "Presently, we are in the phase of mass production of this medicine and the price is less than %10 of the foreign brand. The foreign sample of the medicine is $3000 and we supply it at $200."
/129